Pete Sessions sold AbbVie Inc (NYSE: ABBV)
Pete Sessions (R-TX), a U.S. Representative, has disclosed 1 trade in AbbVie Inc (ABBV) since 2014, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Pete Sessions sold $1,001 - $15,000 of AbbVie Inc (NYSE: ABBV) on April 23, 2014. Since that trade, ABBV is up +729.24% against the S&P 500 up +384.99%, an outperformance of +344.25%.
Data updated
Pete Sessions's ABBV trades vs the price
ABBV is up +729.24% since Pete Sessions sold on April 23, 2014, versus +384.99% for the S&P 500.
Performance since this trade
All Pete Sessions ABBV trades
Pete Sessions & ABBV trading FAQ
Is it legal for Pete Sessions to trade AbbVie Inc (ABBV) stock?
Yes. Members of Congress are allowed to trade individual stocks, including AbbVie Inc (ABBV), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Pete Sessions sell ABBV?
Pete Sessions disclosed a sale of $1,001 - $15,000 of AbbVie Inc (ABBV) on April 23, 2014, according to public STOCK Act filings.
How has ABBV performed since Pete Sessions's trade?
Since Pete Sessions sold ABBV on April 23, 2014, the stock is up +729.24%, versus +384.99% for the S&P 500 over the same period, an outperformance of +344.25%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional ABBV trades?
Quantellect tracks every disclosed congressional trade in AbbVie Inc (ABBV) on the AbbVie Inc congressional trading page, which aggregates filings across all members of Congress.
Pete Sessions's ABBV tradesAll congressional filings for AbbVie IncPete Sessions's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.